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Abstract: Since Huggins defined the androgen-sensitive nature of prostate cancer (PCa), suppression
of systemic testosterone (T) has remained the most effective initial therapy for advanced disease
although progression inevitably occurs. From the inception of clinical efforts to suppress androgen
receptor (AR) signaling by reducing AR ligands, it was also recognized that administration of T in
men with castration-resistant prostate cancer (CRPC) could result in substantial clinical responses.
Data from preclinical models have reproducibly shown biphasic responses to T administration,
with proliferation at low androgen concentrations and growth inhibition at supraphysiological T
concentrations. Many questions regarding the biphasic response of PCa to androgen treatment
remain, primarily regarding the mechanisms driving these responses and how best to exploit the
biphasic phenomenon clinically. Here we review the preclinical and clinical data on high dose
androgen growth repression and discuss cellular pathways and mechanisms likely to be involved in
mediating this response. Although meaningful clinical responses have now been observed in men
with PCa treated with high dose T, not all men respond, leading to questions regarding which tumor
characteristics promote response or resistance, and highlighting the need for studies designed to
determine the molecular mechanism(s) driving these responses and identify predictive biomarkers.
Keywords: high dose testosterone; supraphysiologic androgen; bipolar androgen therapy; biphasic;
BAT; castration resistant prostate cancer; CRPC
1. Introduction
Since the landmark studies of Huggins and colleagues showed the androgen-sensitive nature
of prostate cancer (PCa) [1], suppression of systemic testosterone (T) levels remains the most
effective initial therapy for advanced disease. Although initially highly effective, standard androgen
deprivation therapy (ADT) is characterized by the emergence of resistant tumors over a period of
18–20 months. Median survival after progression, termed castration resistant prostate cancer (CRPC),
is between 1–2 years. An important aspect of CRPC is reactivation of androgen-receptor (AR) signaling,
as demonstrated by analyses of metastatic tumors showing that essentially all known androgen
regulated genes are expressed, including putative drivers of carcinogenesis (e.g., Transmembrane
Protease, Serine 2-ETS-related gene (TMPRSS2-ERG) rearrangements).
From the inception of clinical efforts to suppress AR signaling by reducing AR ligands, it was
also recognized that the administration of T to men with CRPC can result in substantial clinical
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responses, though the reports were largely anecdotal and remissions were highly variable, potentially
due to variability and inadequate increases in the levels of circulating T that were achieved [2–4].
In contrast, abundant data from preclinical models have reproducibly shown biphasic responses of
hormone-sensitive cancers, whereby at physiological T concentrations proliferation is induced, but at
higher, supraphysiological T (SPT) concentrations, proliferation is suppressed and in some instances
apoptotic programs are engaged [5–8]. Though often considered to be an in vitro phenomenon,
recent proof of principle trials using SPT therapy—two in men with CRPC and one in hormone
sensitive PCa produced promising results, showing radiographic response rates of ~50% in men
with CRPC, and favorable prostate specific antigen (PSA) responses in those with hormone naïve
PCa [9–11].
Notably, biphasic responses to hormone concentrations are not unique to PCa and the AR:
When exposed to estradiol (E2), estrogen receptor (ER)-responsive MCF-7 breast cancer cell line
adapted to proliferate in the absence of estradiol undergo an apoptotic response [12–14]. E2 also has
a biphasic effect on the growth of the rat pituitary line GH3 [6]. To date, there is a lack of unifying
mechanisms to explain these effects, though cellular pathways, particularly involving cell cycle control,
provide insights in some systems.
Many questions regarding the biphasic responses of prostate tumors to supraphysiologic androgen
concentrations remain, primarily regarding the mechanisms driving this response and how best
to exploit this phenomenon clinically. To date, efforts to enhance efficacy of SPT have focused
on concomitant manipulation of the androgen receptor (AR), i.e., androgen cycling to induce AR
upregulation and increased sensitivity, but preclinical studies suggest other approaches and drug
combinations may be reasonable to pursue. Here we review the preclinical and clinical literature on
androgen-mediated growth repression and discuss cellular pathways and mechanisms likely to be
involved in mediating this response. Although meaningful clinical responses have now been observed
in men with CRPC treated with SPT [9], not all men respond, leading to questions regarding which
tumor characteristics promote response or resistance, highlighting the need for studies designed to
determine the molecular mechanism(s) driving these responses and identify predictive biomarkers.
2. Physiologic Role of AR in Growth Repression
The AR plays a critical role in the normal development of the prostate gland, although initial
morphogenic activity occurs via mesenchymal AR, not epithelial AR [15]. In the mature prostate,
the small fraction of epithelial cells that are proliferating are localized to the basal compartment, and do
not express AR protein, whereas luminal secretory cells which express AR are quiescent. Introducing
the AR into benign prostate epithelial cells (PrEC), or activating AR function, results in cell growth
arrest and subsequent differentiation toward a luminal phenotype. Detailed studies conducted by
Isaacs et al. determined that the induction of AR activity in PrEC resulted in irreversible growth
arrest in G0, with the maintenance of viability, metabolism, and the expression of proteins that are
associated with terminally-differentiated prostate epithelium, such as PSA [16,17]. Studies using
genetically-engineered mouse models (GEMs) showed that eliminating AR in prostate epithelium
results in a hyper-proliferative cell state with loss of cell differentiation [18–20]. These and other
studies provide compelling evidence that in benign cells with intact mechanisms for regulating cell
proliferation, the AR functions to promote terminal differentiation and a quiescent, G0 state.
3. Oncogenic Role of AR in Prostate Cancer Progression
In contrast to its role in promoting differentiation in normal prostate epithelial cells, AR signaling
in PCa acquires a critical oncogenic role and promotes growth and survival. The mechanism
for this conversion is not fully understood but appears to involve in part a gain of function in
AR induced regulation of myelocytomatosis oncogene cellular homolog (MYC) expression [16,17].
During progression to castration resistance, PCa acquire further changes directed at maintaining AR
signaling in a low androgen environment. These changes include AR overexpression, AR mutations
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that broaden ligand specificity and/or confer sensitivity to adrenal androgens, induction of
constitutively active truncated AR splice variants, alterations in AR coactivators and/or corepressors
that modulate AR stability and ligand sensitivity, and activation of the AR or downstream regulatory
molecules by “cross talk” with other signaling pathways [21–43]. Restoration of full length AR
expression and signaling in a xenograft model was both necessary and sufficient to drive progression
from androgen-dependent to castration resistant growth, sensitizing cells to proliferate in 80% lower
androgen concentrations [33]. Importantly, in these models ligand binding was required for castration
resistant growth, and modest increases in AR expression were sufficient to support signaling in a low
androgen environment.
The clinical relevance of continued AR signaling in promoting CRPC tumor growth is confirmed
by the clinical responses to agents targeting residual androgen pathway activity including the striking
clinical response observed with novel ligand synthesis inhibitors such as abiraterone (ABI), and potent
AR inhibitors such as enzalutamide (ENZ) [44–50].
4. Historical Observations on Androgen Therapy of Prostate Cancer
Interestingly, despite his clear demonstration that androgens were a critical driver of PCa
progression, Huggins himself proposed that both hormonal deprivation and hormonal excess (which he
termed hormonal interference) might be used for therapeutic benefit [51]. A number of case reports
and small series were published between 1950 and 1980. While demonstrating some evidence of
clinical benefit, these studies also showed adverse effects of T administration, though the doses were
generally low, ranging from 25 mg–100 mg daily [2,52]. In a series of three patients, two experienced
temporary symptomatic benefit. In a series of 10 men with CRPC treated with 100 mg T propionate
3 times weekly, one individual, near death at the time of treatment initiation, experienced an objective
response lasting approximately 1 year, although five patients had subjective and objective evidence
of deterioration including pain and pathologic fracture [3]. Two case reports also detail responses to
T therapy, one patient with progression despite orchiectomy and hypophysectomy who responded
to T with a decrease in serum acid phosphatase and symptomatic improvement, and more recent
patient with CRPC treated with T gel replacement with a sustained PSA response lasting for nearly a
year [53,54].
Importantly, simply discontinuing ADT and allowing androgen recovery to a eugonadal state does
not appear to enhance survival; studies of intermittent androgen suppression in metastatic disease,
which also allows gradual T recovery to physiological levels, demonstrated a trend toward inferior
survival compared to continuous ADT [55]. In this regard castration resistant VCaP cells treated with
sequentially higher T doses had less significant apoptotic responses to androgen withdrawal than
those seen in VCaP cells exposed to a single high T “boost” [56].
5. Preclinical Observations on Androgen-Mediated Growth Repression of Prostate Cancer
Although historical support for the clinical benefit of androgen therapy for PCa has been mixed,
the paradoxical inhibitory response of PCa to supraphysiological androgens has been demonstrated in
multiple in vitro and in vivo studies. These studies are summarized below, and a more detailed review
of findings in each pre-clinical model is provided in Appendix A. The LNCaP cell line is widely used as
a model for mechanistic studies of PCa molecular biology, including AR function. Several groups have
reproducibly demonstrated a biphasic proliferative response to androgen, with minimal proliferation
in the absence of any androgen, high rates of proliferation at concentrations of dihydrotestosterone
(DHT) or the non-metabolizable androgen (R1881) of 0.1 nM, and cell cycle arrest with concentrations
of DHT/R1881 exceeding 1.0 nM (equivalent to ~5–10 nM T) [7,8,57]. This effect has been observed in
other PCa lines that natively express the AR as well as cells engineered to express the AR (summarized
in Appendix A Table A1).
Within a tumor model, the response of cells to androgen-repressed growth is often more
pronounced in castration resistant (CR) variants that have been derived after serial passage in
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androgen-depleted media, whereby the growth repressing effects can occur at 10–100 fold less androgen.
Progression to the CR state is often accompanied by an increase in AR levels and transcriptional
activity, suggesting the elevated AR levels in the more refractory tumor cells sensitizes these models to
repression at lower androgen doses. In the transition from the androgen sensitive (AS) LNCaP 104S
variant to the androgen independent (AI) 104R line (after 8–11 months in charcoal stripped (CS) media),
the repressive dose of R1881 is left-shifted two orders of magnitude, from 1 nM (10−9) to 0.01 nM
(10−11), accompanied by increased AR expression and activity suggesting an increased sensitivity to
androgen signaling [58]. An AI subline of MDA PCa 2ba shifts from being androgen-stimulated for
growth to being androgen suppressed for growth with an increase in AR levels [59,60]. Similar to
LNCaP, the growth of CWR22 cells is biphasic and the suppression is left shifted in the AI line
CWR22R [61].
Exemplifying the known heterogeneity of advanced disease, PCa cell lines demonstrate a diversity
of androgen-mediated growth responses. Importantly, an androgen-repressed growth phenotype is
not exclusively associated with elevated AR levels, nor do low AR levels preclude androgen-repressed
growth. Some PC cells with relatively low AR such as ARCaP still show a strong androgen-repressed
phenotype [62]. In contradistinction to CWR22 cells, 22Rv1, another AI line derived from CWR22R,
is AS for growth without a biphasic response [63]. The mechanism(s) underlying these responses
and why the growth repressive effect of SPT is not uniformly observed in all AR + PC cells are
not understood. In tumors where the repressive response is left shifted with increased AR it is
not known whether additional mechanisms are operative. Nor is it known to what extent the
mechanism of AR-mediated growth-suppression occurs by similar or different mechanisms in the
different androgen-repressed cell lines.
Notably, despite compelling preclinical evidence that the androgen-repressive effect is often
magnified in CR tumor variants, clinical observations do not necessarily support this. In the early
studies of Fowler and Whitmore 45 of 52 men had unfavorable responses to exogenous T, and the
proportion of men who had an unfavorable response was higher in those who had been on prolonged
hormone suppression (94%) compared to castration-naïve men (25%), or men in early stages of
hormone suppression (36%) [64]. It is possible that while repressive responses to SPT may be enhanced
in CR tumors with upregulated AR, growth-promoting responses to physiologic T may be similarly
enhanced in CR tumors.
6. Contemporary Clinical Studies of Testosterone Therapy for Prostate Cancer
Several contemporary trials of T treatment have been conducted (summarized in Table 1), two in
which physiologic T levels were achieved and minimal responses were observed [65,66], and three
in which T levels achieved were truly supraphysiologic and a clear subset of men showed clinical
responses [9–11].
6.1. Studies of Continuous Testosterone Treatment
Morris et al. conducted a Phase 1 trial of 12 men with CRPC who were treated with T via 5 mg
transdermal patch or 1% gel for 1 week, 1 month, or until disease progression. T treatment resulted in
raising T levels to the normal physiological range although DHT levels were supraphysiologic in a
subset of men. One patient achieved a PSA decline of >50% from baseline, but no objective responses
were seen, with a median time to progression of 84 days (range 23–247 days) [65].
Szmulewitz et al. conducted a randomized trial evaluating transdermal T at 25, 5.0 or 75 mg/day
in 15 men with CRPC but minimal metastatic disease [66]. Notably, serum T levels increased from
castrate to ~300 ng/dL, essentially a eugonadal concentration. Increases in PSA, which may rise
with T replacement, rather than other objective measures of disease progression were responsible for
the majority of progression events. (20%) of patients demonstrated a decrease in PSA (largest was
43%), with a median time to progression of 9 weeks (range: 2–96 weeks). One patient experienced
symptomatic progression. There was no significant improvement in quality of life (QoL).
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Table 1. Contemporary Trials of High Dose Androgen Therapy.
Patient Population No. ofPatients
Treatment
Regimen Serum T Level PSA Response
Objective
Response
Median Time
to Progression
Caner Related
Adverse Effects Ref.
CRPC (disease burden
or symptoms not
designated)
12
T via 5 mg
transdermal patch
or 1% gel for
1 week, 1 month,
or until disease
progression
physiologic
(342–876 ng/dL)
1 patient had PSA
decline
>50% from
baseline
none 84 days(23–247 days) [65]
CRPC with minimal
metastatic disease 15
transdermal T at 25,
5.0 or 75 mg/day
physiologic
(94–824 ng/dL)
3/15 (20%) had
PSA declines from
baseline (largest
decline 43%)
none 63 days(14–672 days)
one patient with
symptomatic
progression
[66]
Asymptomatic CRPC
with low to moderate
metastatic burden
16
T (400 mg IM day
1 of 28) and
etoposide (100 mg
oral daily; days 1 to
14 of 28)
T > 1500 ng/dL
(~50 nM) at 2 days after
T injection (range 920 to
>3200 ng/dL), above
600 ng/dL at 2 weeks,
and 150 ng/dL by
28 days
7/14 (50%) had
PSA declines from
baseline (≥50%)
radiographic
responses in
5/10 (50%),
and 4 continued
on treatment for
≥1 year
11 months (3 to
not reached)
2 patients were not
evaluable because
they came off study
after only one cycle
of therapy due
to toxicity
[9]
CRPC post progression
on enzalutamide 30
alternating 3 month
cycles of BAT
(T 400 mg IM on
days 1, 29 or 57),
followed by
3 months of
ADT alone
not reported
9/30 (30%) men
achieved a
≥50% decline in
PSA from baseline
50% of patients
achieving an
objective
radiographic
response
8.6 months
(4.7 to not
reached)
3 patients
progressed per
RECIST criteria and
3 had unconfirmed
progression on
bone scan
[11]
Asymptomatic
hormone naïve with
low metastatic burden
or biochemically
recurrent disease,
who achieved
PSA < 4 ng/dL after
6 months of ADT
29 T 400 mg IM ondays 1, 29, and 57 not reported
17/29 (59%)
achieved primary
endpoint of
PSA < 4 ng/dL
after 18 months
4 of 10 evaluable
patients had
complete and
4 had partial
responses (80%)
not given
3 patients taken off
study prior to
completing 2 cycles
due to concerns for
early progression
[10]
CRPC: castration resistant prostate cancer; T: testosterone; PSA: prostate specific antigen; BAT: bipolar androgen therapy; IM: intra-muscular; ADT: androgen deprivation therapy.
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6.2. Studies of Bipolar Androgen Therapy (BAT)
In contrast to these studies in which T was administered in continuous manner, the group of
Denmeade and Isaacs has pioneered an approach termed Bipolar Androgen Therapy (BAT) [67].
Overexpression of AR is one of the most common molecular hallmarks of CRPC [68], and it
was hypothesized that by rapidly cycling T levels between the supraphysiological (~1500 ng/dL)
and near-castrate (~150 ng/dL) range, adaptive changes in AR expression would be blunted,
thereby delaying the emergence of resistance. Data from these investigators has also suggested
that AR becomes critically involved in the DNA replication licensing required for PCa cell proliferation.
As discussed more fully below, increased ligand may over-stabilize AR on DNA, preventing its
degradation and inhibits DNA relicensing, resulting in cell death in the subsequent cycle [69–71].
Schweizer et al. reported the first clinical experience with this approach: 16 men with
asymptomatic metastatic CRPC were treated with 400 mg of T intramuscularly (IM) monthly [9].
Notably, 2 days after T administration, serum T levels exceeded 1500 ng/dL (~50 nM) and fell to
<200 ng/dL at the end of each 28 day cycle. PSA declines (≥50%) were observed in nearly one-third
of patients, radiographic responses were observed in 50% of men, and four continued on treatment
for ≥1 year. At progression, ADT or AR inhibitory therapy produced responses in 100% of men,
suggesting that BAT may restore sensitivity to ADT [9]. Importantly, no patient developed worsening
pain due to PCa, nor were there any other skeletal events or evidence of worsening urinary obstruction.
In a follow up study recently reported by Teply et al, men with CRPC who had progressed on
ENZ went on to receive BAT (n = 30) [10]. This study documented similar activity in response to BAT,
with 9 of 30 (30%) men achieving a ≥50% decline in PSA from baseline and 50% of patients achieving
an objective radiographic response. Twenty-nine patients progressed on BAT and went on to be
re-challenged with ENZ. Fifteen of 29 (52%) had a PSA decline≥50%, however, there were no objective
radiographic responses and time to progression was generally short following ENZ re-challenge.
In another study in hormone naive patients, 29 men with low metastatic burden or biochemically
recurrent disease who achieved PSA < 4 ng/dL after 6 months of ADT were treated with alternating
3 month cycles of BAT (given as IM injections of 400 mg T cypionate or enanthate on days 1, 29 or
57), followed by 3 months of ADT alone [10]. The primary endpoint was the percent of patients
with a PSA < 4 ng/dL after two rounds of BAT-ADT (i.e., following the 18-month treatment period).
Serum androgen levels were not reported. Three of 29 patients were taken off study prior to completing
two cycles due to concerns for early progression. However, the 26 patients that completed the study as
designed achieved a PSA below their pre-treatment baseline, with 17/29 (59%) achieving the primary
endpoint of PSA < 4 ng/dL after 18 months, including three patients who had an undetectable PSA
(<0.2 ng/mL) at the18-month time point. Of 10 men with measurable disease, four complete and four
partial responses were observed. Notably, five of seven patients who did progress to CRPC by the end
of the study responded to subsequent treatment with anti-androgen, again suggesting that BAT may
restore sensitivity to ADT Treatment was associated with favorable improvement in QoL, although
QoL diminished over the course of each cycle of BAT, presumably due to T levels falling below the
normal range.
BAT is currently being tested in a large (n = 180) randomized trial (NCT02286921;
TRANSFORMER) in asymptomatic mCRPC patients who have failed on abiraterone. In this study,
BAT is being compared with ENZ with a primary end point of progression-free survival (PFS).
While the more substantive clinical benefit observed in the studies of BAT vs. other contemporary and
historical studies of androgen treatment may reflect the bipolar dosing strategy, it is likely that it also
is related to the fact that these are the only studies in which supraphysiologic androgens have been
achieved. Importantly, the relative dearth of patients experiencing clinical deterioration on T treatment
compared to historical studies highlights the importance of patient selection, which, in modern studies,
was limited to asymptomatic patients with limited metastatic disease.
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7. Proposed Mechanisms of Androgen-Mediated Growth Repression
Numerous studies utilizing PCa models with endogenously expressed AR, as well as cell models
with exogenously driven increases in AR, have shown that increased AR expression and/or ligand
driven activation may result in growth inhibition, variably attributed to cell cycle arrest in G1/S or
the subG0/G1 phase, and/or frank DNA fragmentation and apoptosis [18,36,70,72–77]. A number
of mechanisms underlying the growth inhibitory effects of SPT have been proposed (summarized in
Figure 1) including: I. Cell Cycle Arrest; II. Repression of MYC and S-phase kinase-associated protein
2 (SKP2); III. Apoptosis; IV. Disruption of AR-Mediated DNA Licensing; V. Transcriptional Repression
of AR and AR Variants; VI. Transcriptional Reprogramming and Differentiation; and VII. Induction of
Cellular Senescence or Quiescence; VIII. Induction of DNA Damage.
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Figure 1. Potential mechanisms for repression of prostate cancer growth by high dose androgen.
(A) AR activation in context of high dose androgen (denoted by light blue squares) may lead to
transcriptional repression of myelocytomatosis oncogene cellular homolog (MYC) and its target gene
S-phase kinase-associated protein 2 (SKP2), with loss of ubiquitin-mediated degradation of the G1
cyclin dependent kinase (CDK) inhibitors p21cip1 and p27kip1, l ading to (B) G1 arrest. (AR can
also directly induce expressio of p21cip1 via an androgen response elemen (ARE) in its proximal
promoter). (C) Ligand-dependent stabilization of AR during mitosis may inhibit AR degradation
in M phase, preventing relicensing for DNA replication during G1 resulting in S phase arrest.
(D) Androgen induced repression of genes that promote epithelial to mesenchymal transition (EMT)
such as (sex determining region Y)-box 2 (SOX2), and expression of genes important in normal
differentiation such as sister chromatid cohesion protein cohesion associated factor B (PDS5B (also
known as androgen-induced proliferation inhibitor (APRIN)) and promyelocytic leukemia zinc finger
protein (PLZF), may promote a more differentiated less aggressive cell state. Through recruitment of
hypo-phosphorylated retinoblastoma protein (RB) to shared AR/RB/E2F binding sites, agonist-liganded
AR repres es gen s involved in DNA replication, poten ially leading to transcr ptional reprogramming
toward a less proliferative state. (E) Activated AR may act as a transcriptional repressor at certain AR
binding sites (ARBS) via recruitment f lysine-specific histone demethylase 1 (LSD1) and demeth lation of
activating histone marks, resulting in decreased expression of full length AR and downstream generation
of spliced variants. (F) AR-induced production of reactive oxygen species (ROS) leading to decreased RB
phosphorylation and repression of E2F target genes may result in formation of senescence-associated
heterochromatic foci (SAHFs). (G) Androgen signaling leads to co-recruitment of AR and topoisomerase
II beta (TOP2B) and TOP2B-mediated DNA double stranded breaks (DSBs) in regulatory regions of
AR target genes, potentially leading to DNA damage and apoptosis, particularly in the setting of DNA
damage repair (DDR) deficiency (such as mutations in ataxia-telangiectasia mutated gene (ATM) or
breast cancer 2 (BRCA2)). X: inhibition of gene expression; +: induction of gene expression.
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7.1. Cell Cycle Arrest
De Launoit et al. showed that at the maximal proliferative dose of DHT (0.1 nM), the fraction of
androgen-sensitive LNCaP cells in G0–G1 phase significantly decreased (at 36 and 48 h), reflected by
an increase in cells in the S and G2/M phases, whereas at growth inhibitory doses of DHT greater than
0.1 nM, an increase in the number of cells in G0–G1 phase was observed, with a significant decrease in
cells in the S and G2/M phases [78,79]. G1 arrest was also shown in the androgen independent LNCaP
104-R1 and 104-R2 sub-lines treated with 10 nM R1881, with the maximum decline in the S phase
fraction at 72 h after androgen treatment [57]. However, R1881 had no effect on cell cycle distribution
in the related androgen-insensitive LNCaP R2-Ad subline [80]. Treatment with 1 nM R1881 yielded a
cell cycle arrest in the androgen-repressed MOP, ME, and JAC LNCaP sublines, with an increase in the
proportion of cells arrested it the G1 phase and a compensatory decrease in cells in the S and G2/M
phases [76].
SPT in PC-3 cells with exogenous expression of AR has also shown a G0/G1 growth arrest.
Litvinov et al. reported that overexpression of AR in PC-3 cells caused growth inhibition via G1 arrest,
associated with increased expression of the cyclin dependent kinase (CDK) inhibitor p21 (WAF1/CIP1)
(a known AR-regulated gene via an ARE in its proximal promoter [81]), as well as an increase in p27kip1
and suppression of p45/SKP2 (normally upregulated in G1 to target the CDK inhibitor p27kip1 for
proteosomal degradation) [69,82]. These findings were confirmed by Kokontis et al., using PC3 cells
re-expressing either the wild type AR (PC3-AR) or the mutant LNCaP AR (PC3 LNCaP-AR) [83].
7.2. Repression of SKP2 and MYC
Exposure of LNCaP and LNCaP-derived sublines to SPT has been shown to repress the expression
of SKP2 [84]. SKP2 is a substrate-targeting subunit of the SCF E3 ubiquitin ligase complex which
phosphorylates p21cip1 and p27kip1, targeting them for ubiquitination and degradation. p27kip1 is a
cyclin-dependent kinase inhibitor which is encoded by CDKN1B gene [85]. The encoded protein was
shown to inhibit the cyclin E/CDK2 complex in androgen-treated LNCaP cells [57,79]. LNCaP cells
treated with SPT show elevated levels of p27kip1 protein, consistent with impairment in the
degradation program following the reduction of SKP2 [57,79,80,86].
One proposed mechanism involves AR-mediated repression of MYC (transcription), with concomitant
repression of MYC target genes, which include the ubiquitin ligase SKP2, and thereby upregulation
of the G1 cyclin dependent kinase (CDK) inhibitor p27Kip1 which is regulated by SKP2-mediated
degradation [16,80,83]. Although not shown in PCa, SKP2 is a direct transcriptional target of MYC
in tumor cells including leukemia and neuroblastoma [87,88]. Conversely, SKP2 regulates MYC
ubiquitination and stability and serves as a transcriptional coactivator for MYC [89].
In the androgen-sensitive LNCaP 104-S cells, R1881 increased levels of MYC and SKP2 expression
and decreased levels of p27kip1 [80]. In contrast, R1881 decreased the levels of MYC and SKP2
and increased p27kip1 in the more strongly androgen-repressed LNCaP 104-R cell lines [80,83].
Moreover, overexpression of this protein along with MYC countered androgen-mediated growth
suppression in castration resistant 104-R LNCaP cells [80,83]. In the androgen-insensitive R2Ad cell
line, R1881 did not alter the levels of MYC, p27kip1, or SKP2 [90].
SKP2 is also a transcriptional target of E2F [91], and changes in its expression may reflect
AR-mediated changes in RB induction of E2F. Jiang et al. demonstrated that SKP2 transcription
is directly suppressed by an RB family member, the p107 pocket protein, following SPT treatment [82].
Repressing p107 partially blocked SKP2 repression following exposure to SPT, though whether SKP2 or
p107 inhibition altered SPT growth arrest was not determined. Notably, SPT was shown to reduce p107
phosphorylation, though the AR-regulated phosphatase (potentially induced) or kinase (potentially
repressed) responsible for this effect was not identified.
To date, these findings have not been validated across models that respond or resist SPT, and the
mechanism(s) by which MYC or SKP2 are regulated by SPT have not been identified.
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7.3. Apoptosis
While the role of androgen has been shown to be anti-apoptotic in androgen-dependent PCa
cells [92], androgen may also induce apoptosis in castration resistant cell lines. Treatment of MOP cells,
a castration resistant and androgen-repressed subline of LNCaP, with 100 nM R1881 resulted in an
increase in the apoptotic index, with 37% of cells showing nuclear fragmentation and inter-nucleosomal
DNA breaks after 6 days of treatment [75]. In the castration resistant 104-R1 LNCaP cell line,
AR promoted B-cell lymphoma 2 (BCL2) associated x, apoptosis regulator (BAX)-mediated apoptosis,
was involved in mitochondrial translocation of BAX, and addition of androgen potentiated AR-related
BAX translocation and the induction of apoptosis [77]. BAX is a member of the BCL-2 family that
when activated, initiates apoptosis [93]. Knocking down of AR by siRNA in LNCaP 104-R1 cells
resulted in failure of BAX to induce apoptosis. Similarly, while UV induced apoptosis in 40% of the
parental LNCaP cells, only 9% of the cells with AR knockdown underwent UV-induced apoptosis [77].
Moreover, addition of androgen potentiated BAX-mediated apoptosis, as was seen in 37% of cells
treated with 1 nM R1881 compared to only 19% cell death induced by BAX alone. Androgen also
induced apoptosis in PC-3 cells engineered to overexpress AR [73]. However, AR-dependent
UV-induced apoptosis was also achieved in the same LNCaP cell line in an androgen independent
manner, via AR transcriptional downregulation of p21cip1 expression [94]. p21cip1 is known to have
anti-apoptotic and tumor promoting functions, and in the LNCaP 104R model AR was shown to prime
cells for apoptosis via down-regulation of basal p21cip1 expression [94].
7.4. Disruption of AR-Mediated DNA Licensing
Normally, licensing factors are degraded in M phase or early G1 phase to allow for relicensing and
re-initiation of DNA replication in the next cell cycle [95]. Litvinov et al. and Isaacs et al. have shown
AR to interact with the pre-RC and DNA replication machinery in early G1 phase, suggesting it may act
as a “licensing” factor for initiation of DNA replication in the subsequent S phase [69,96]. They suggest
that excessive ligand-dependent stabilization of AR during mitosis, due to either increased AR or
increased ligand, inhibits AR degradation in M phase. This results in a fraction of AR remaining bound
to origin of replication sites, preventing relicensing during G1 and resulting in S phase arrest. As AR
levels increase with ADT and decrease with normalization of androgen levels they have proposed that
rapid androgen cycling between ADT and supraphysiogic androgen levels will prevent the adaptive
down regulation of AR levels (that can occur in response to a slow rise in androgens) that would allow
re-licensing and cause a poor inhibitory response to subsequent androgen treatment.
Using LNCaP, LAPC4 and CWR22Rv1 PCa cells, a cyclic proteasome-dependent degradation
of AR during G1 was observed, along with co-immunoprecipitation (co-IP) of AR with replication
complexes (RC), and co-IP of AR with origin of replication complex 2 (ORC2) in four of seven human
CRPC metastases, suggesting AR may function as a licensing factor for DNA replication in cells that
are androgen-sensitive for growth. In contrast, they do not observe binding of AR to RCs in cells in
which liganded AR does not drive growth (the E006AA PCa line, and a prostate stromal line) [69,71].
The impact of high dose androgen on these parameters was not directly tested in LAPC4 or 22Rv1
cell lines. However, in parental LNCaP cells, a LNCaP derivative with castration resistant growth,
in 22Rv1 cells overexpressing AR, and in PC-3 cells overexpressing AR, androgen-mediated growth
repression was associated with a marked increase in the percent of mitotic cells with detectable AR
expression (i.e., 85% vs. 0.5% in untreated), consistent with a role of AR degradation in permitting
relicensing of DNA for subsequent replication. in these cells.
However, while cyclic degradation of AR in 22Rv1 cells, and association of AR with RC’s in
22Rv1 and VCaP cells was similarly observed, a repressive effect of androgen on 22RV1 does not occur;
androgen remains stimulatory at 10–6 M T in the 22Rv1 model [63]. These observations suggest that a
potential impact of ligand on AR stabilization and interference with proper DNA re-licensing may not
be the mechanism by which SPT mediates growth inhibition in all cases.
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7.5. Transcriptional Repression of AR and AR Variants
To the extent that AR and AR splice variants are drivers of CRPC progression, mechanisms
that repress their expression may lead to decreased cell growth. Studies by the Balk group have
shown that AR gene expression is directly repressed by the AR through recruitment of lysine-specific
histone demethylase 1 (LSD1) to an AR Binding Site (ARBS) region termed ARBS2 of which a segment
of ~400 bp is highly conserved across species [97]. Agonist liganded AR was shown to decreases
AR gene expression in castration resistant VCS2 cells (derived from VCaP cells) by functioning
as a transcriptional repressor through recruitment of LSD1 and demethylation of histone 3 lysine
4 (H3K4)me1,2 [97]. AR also repressed aldo-keto reductase family 1 member C3 (AKR1C3) and
hydroxysteroid 17-beta dehydrogenase 6 (HSD17B6) through a similar LSD1 dependent mechanism,
indicating that the agonist liganded AR directly mediates a physiological intracellular negative
feedback loop to regulate AR activity. Moreover, in all cases the androgen-stimulated down-regulation
was decreased or abrogated by treatment with the LSD1 inhibitor pargyline. The role of LSD1 inhibition
in the context of SPT has not been explicitly evaluated, although loss of LSD1 or LSD1 activity has the
potential to abrogate SPT effects by inhibiting generation of AR repressive complexes on key targets,
or may enhance SPT effects by increasing levels of AR itself.
Whether SPT results in dynamic changes of AR expression associated with growth inhibition
in the clinical setting has not been assessed, but has been suggested in several pre-clinical models
in vivo. Thelen et al. compared the growth of castration sensitive VCaP cells maintained in 10% fetal
bovine serum (FBS) to a subline adapted to growth in 1 nM T after implantation in intact (non-castrate)
nude mice [56]. Notably, the VCaP cells grown in FBS showed a significant growth disadvantage
compared to the subline adapted to T in cell culture. Transcript levels of AR and ARV7 were rapidly
downregulated by 1 nM T in the VCaP cells maintained in 10% FBS in vitro, and were also lower in
the xenografts grown in intact mice than in the parental cells passaged in 10% FBS.
Nakata examined growth inhibition by androgen in JDCaP-hr, an AR and ARV7 positive cell
line derived from the castration recurrent outgrowth of a JDCaP xenograft (generated from the skin
metastasis of a Japanese CRPC patient) [98,99]. Expression of full length AR (AR-FL) and splice
variant 7 AR (AR-V7) mRNA was upregulated by 10-fold in JDCaP-hr compared with that in JDCaP.
T suppressed the growth of JDCaP-hr in vitro and in vivo in association with downregulation of AR
and ARV7 expression, while silencing of AR-V7 but not AR-FL markedly suppressed cell growth.
A recent trial of BAT in patients who progressed on ENZ did not show a clear correlation
between response and modulation of AR-FL or AR-V7 transcript levels in circulating tumor cells [11].
However, further studies, potentially with assessment of tumor AR expression, are needed to fully
evaluate the association of AR modulation with response to SPT.
7.6. Transcriptional Reprogramming and Differentiation
As decreased AR signaling following ligand depletion leads to oncogenic changes in the
AR-cistrome, transitioning back from low- to high-T conditions may reprogram the AR-cistrome
toward a more differentiated state [97,100]. In addition to showing that AR may directly repress
its own expression, the work of Cai et al. described above also showed that agonist liganded AR
suppressed the expression of multiple genes mediating DNA synthesis and cell cycle progression,
while it increased the expression of genes mediating synthesis of lipids, amino acids, and other
metabolic processes. This lead the authors to postulate a model whereby androgen levels in CRPC cells
are adequate to stimulate AR activity on enhancer elements of genes mediating certain critical metabolic
functions such as lipid synthesis (that are sensitive to lower levels of androgens), but are not adequate
to effectively recruit AR and LSD1 to suppressor elements in multiple genes that negatively regulate
AR signaling and cellular proliferation. In a subsequent publication this group demonstrated that AR
causes transcriptional repression of multiple genes involved in DNA replication via interactions with
RB1. In particular, SPT was able to induce AR binding to regulatory regions of genes involved in DNA
replication and repress their transcription through recruitment of hypo-phosphorylated RB [101].
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Alternatively, Ruan et al. have recently demonstrated that SKP2 can bind and stabilize expression
of Twist protein, leading to acquisition of epithelial-mesenchymal transition (EMT) and cancer stem
cell (CSC) characteristics [102]. Genetic or pharmacologic depletion of SKP2 reverted these effects and
re-sensitized CRPC cells to chemotherapy. Whether AR-mediated repression of MYC, or AR-mediated
changes in RB induction of E2F are the upstream factors responsible for the decreased SKP2 expression,
these data provide another potential mechanism for the cellular reprogramming of CRPC cells treated
with SPT toward a less aggressive tumor biology.
The repression or induction of specific genes involved in transcriptional programming and
differentiation has also been linked to androgen induced proliferative arrest in PCa cells. SOX2 is
an androgen repressed gene that is upregulated in CRPC and has been shown to stimulate
epithelial-to-mesenchymal transition (EMT) as well as mediate lineage plasticity from (AR)-dependent
luminal epithelial cells to AR-independent basal-like cells [103–105]. Endogenous expression of SOX2
in prostate epithelial cells, human embryonic stem cells, and PCa cells is repressed by AR signaling
(via an enhancer element within the SOX promoter), and loss of SOX2 expression has been shown to
inhibit growth of the castration-resistant CWR-R1 PCa cell line [103]. While not specifically evaluated,
these data suggest a possible role for androgen induced repression of SOX2 in repressing tumor growth
via promoting a more differentiated luminal epithelial cell state.
PDS5B (APRIN, AS3) was initially discovered as a gene induced in LNCaP PCa cell lines and rat
prostate cells undergoing androgen induced proliferative arrest [5,106]. It was later shown that the
basic features of PDS5B (lineage, domain architecture, unique high mobility group (HMG) domains and
heterochromatin localization) were consistent with that of a chromatin regulator, suggesting PDS5B
may serve as a regulator of chromatin architecture in hormonal differentiation [107]. Although not
assessed in PCa models to date, PDS5B was shown to be a critical mediator of differentiation in
embryonal carcinoma stem cells, with PDS5B silencing resulting in arrested differentiation at a
transient, proliferative progenitor phase characterized by loss of contact signaling, hormone resistance,
and continued proliferation [108].
Promyelocytic leukemia zinc finger protein (PLZF, ZBTB16) is another androgen induced
transcription factor gene widely involved in regulation of proliferation, differentiation, and stem
cell maintenance that could potentially play a role in androgen-mediated growth repression [109].
PLZF expression is rapidly induced by androgen in PCa cell lines, and expression of PLZF has been
shown to inhibit proliferation in LNCaP and 22RV1 cells [110,111]. Notably, transcript expression
of PDS5B ranges nearly an order of magnitude in CRPC tumors [112], while PLZF expression is
reduced/lost in up to 86% of metastatic PCa specimens, with 5–7% of CRPC specimens harboring
homozygous PLZF deletions [110,113], suggesting a possible role for androgen-induced expression of
PDS5B or PLZF in promoting induction of a more differentiated cell state.
7.7. Induction of Cellular Senescence or Quiescence
Senescence is an irreversible cell cycle arrest associated with changes in cell morphology and gene
expression that occurs during the normal embryogenesis [114]. Exogenous re-activation and induction
of cellular senescence has been proposed as a potential target for cancer therapy [115].
Several mechanisms of induction of senescence by high dose androgens in PCa cells have been
described. Roediger et al. demonstrated a dose-dependent induction of G1/G0 cell cycle arrest and
senescence associated beta galactosidase activity (SA beta-Gal) in LNCaP, C4-2 and AR-expressing PC-3
PCa cell lines treated with R1881 at 1 nM or higher concentrations, and in malignant prostate tissues
treated ex vivo with R1881 at 10 nM or higher concentrations [116]. Formation of senescence-associated
heterochromatic foci (SAHFs) has been shown to coincide with stable repression of E2F target genes in a
RB-dependent manner, and E2F1 regulates expression of its own gene by a positive feedback loop [117].
Accordingly, they showed E2F1 was localized to SAHF, and further that the p16-RB-E2F1 pathway
was required for this effect, as knockdown of p16 by siRNA decreased formation of heterochromtic
foci. SA beta-Gal activity was induced after only 3 h of androgen treatment suggesting a non-genomic
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rapid signaling response, mediated in part via the Rous sarcoma oncogene (SRC)- phosphatidylinositol
3-kinase (PI3K)- serine/threonine kinase 1 (AKT) signaling pathway, as treatment with a SRC, PI3K or
AKT inhibitor each abrogated the effect (whereas inhibitors of other factors downstream of SRC
e.g., mitogen-activated protein kinase kinase (MEK), mitogen-activated protein kinase 14 (MAPK14,
also known as p38), signal transducer and activator of transcription 3 (STAT3), and mechanistic target of
rapamycin kinase (mTOR), did not). Mirochnik et al. demonstrated induction of senescence in LNCaP
cells and PC-3 cells engineered to express AR via two mechanisms, first, via AR induced expression of
p21cip leading, via an unidentifed mechanism, to decreased expression of p63 (a p53-related protein
that opposes cellular senescence) and second, via AR induced expression of reactive oxygen species
(ROS) leading to decreased RB phosphorylation and repression of E2F target genes [118].
In contrast to senescence, quiescence is a reversible growth arrest in G0/G1 that generally requires
persistence of an external growth condition for its maintenance. However, Bui et al. recently reported
the androgen-mediated induction of a self-sustained quiescent state in LNCaP and VCaP cells that
was dependent on culturing cells at low density, and associated with induction of oxidative stress,
a sustained redox imbalance, and transforming growth factor-beta (TGF beta)/bone morphogenic
protein (BMP) signaling [119]. Treatment with R1881 induced expression of stress, differentiation
and mothers against decapentaplegic homolog (SMAD) signaling markers comprising a dormancy
signature that the authors had previously identified in PCa cells rendered quiescent by culture
at low density in hypertonic medium. Notably, transient treatment with R1881 at doses greater
than 0.2 nM for 7 days caused a sustained decrease in cloning efficiency that persisted for at least
10 days after androgen withdrawal. However, growth arrest could be reversed by treatment with the
anti-oxidants glutathione, or N-acetylcysteine, or by inhibition of TGF beta/BMP mediated SMAD
phosphorylation. The authors propose that utilization of high dose androgen therapy as early as after
radical prostatectomy, or possibly biochemical relapse, when cancer cells are still dispersed and solitary
may have most efficacy as stable induction of the self-sustained quiescent state in their studies only
occurred at low cell density.
7.8. Induction of DNA Damage
Although it is well established that ADT causes DNA damage, recent data have also shown that
high androgen concentrations induce dsDNA breaks (DSB) in PCa cells that can lead to chromosomal
rearrangements such as the TMPRSS2-ERG fusion [120], and may represent one mechanism whereby
SPT inhibits proliferation. In particular, studies have shown that androgen signaling leads to
co-recruitment of AR and topoisomerase II beta (TOP2B), and to TOP2B-mediated DNA DSBs at
regulatory regions of AR target genes in PCa cells [120]. Moreover, treatment of PCa cells with
etoposide, a TOP2-inhibitor that prevents resolution of TOP2B-induced DSBs, led to enhanced
androgen-induced DSBs in the treated cells [120]. This provided rationale for inclusion of etoposide in
the first study of BAT reported in men with CRPC [9]. Although the specific effect of this agent on
the response to BAT was not fully dissected, a recent case report documented an extreme response
following BAT in a patient with inactivating ataxia telangiectasia mutated (ATM) and breast cancer
2 (BRCA2) mutations, providing support for the concept that DNA damage can sensitize to SPT [121].
These data provide rationale for further studies to test the hypothesis that combining SPT and with
DNA damaging agents such as PARP inhibitors (PARPi) will result in clinical responses in men
with CRPC.
8. High Dose Estrogen Therapy for Breast Cancer–Clinical and Experimental Evidence
Similar to the dual growth-promoting and growth-repressing effects of androgens in PCa,
estrogens occupy a similarly paradoxical role in the biology and treatment of breast cancer,
although with a more substantial history of clinical use. The efficacy of synthetic estrogens for
advanced breast cancer was first described by Haddow in 1944, followed by a number of clinical trials
that made estrogens the standard of care in postmenopausal patients with advanced breast cancer
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from the early 1960s onwards (reviewed in [122,123]). A critical observation in these early studies
was the necessity of a ‘gap period’ following development of menopause, in that response rates to
diethylstilbestrol (DES, 5–15 mg/day) or ethinyl estradiol (EE, 1.5–3 mg/day) were substantively
higher (~30–40%) in women who were at least 5 years post-menopause compared to those who were
not (~5–10%).
When the non-steroidal anti-estrogen tamoxifen was introduced in the 1970s for the treatment
of advanced breast cancer, it was compared in clinical trials to DES or EE as the current standard
of care. Notably, the response rate was generally comparable to that seen with estrogen treatment,
but the consistently superior side effect profile of tamoxifen resulted in its uniform adoption for the
first line treatment of advanced breast cancer. Estrogen therapy was essentially abandoned until
studies in the 1990’s demonstrating the efficacy of this approach in patients who were resistant to
anti-estrogens began to emerge. A number of studies evaluating DES or EE in heavily pre-treated
post-menopausal women who were resistant to prior hormonal therapies including tamoxifen and/or
aromatase inhibitors demonstrated objective response rates in approximately 30% of patients [122,123].
These observations renewed interest in the clinical and biological mechanisms underlying the activity
of high dose estrogens in breast cancer.
Similar to the data for PCa, work by several investigators demonstrated that long term adaptation
of breast cancer cells in vitro or in vivo to estradiol deprivation (and subsequently, to tamoxifen
treatment) induces sensitivity to estradiol-mediated growth inhibition [124,125]. In contrast to the
relative diversity of mechanisms proposed for androgen-mediated inhibition of PCa cell growth,
the primary cause of estrogen-mediated growth inhibition in breast cancer cells appears to apoptosis,
albeit via various effector mechanisms [126]. Notably, the conformation of the ER complex, which is
dependent on the shape of the estrogenic ligand, can modulate the apoptotic effect, with class I planar
estrogens (e.g., estradiol) triggering apoptosis after 24 h and class II angular estrogens (e.g., bisphenol
triphenylethylene) delay the process until after 72 h [127].
A number of mechanisms for estrogen-induced apoptosis have been described. Work by the group
of C. Jordan has delineated a SRC-dependent estradiol-mediated induction of endoplasmic reticulum
stress and inflammatory responses that initiates an unfolded protein response, followed by apoptosis
through the intrinsic (mitochondrial) pathway with subsequent recruitment of the extrinsic (death
receptor) pathway to complete the process [122]. An estradiol mediated activation of protein kinase
AMP-activated catalytic subunit alpha 1 (AMPK) in long term estrogen deprived (LTED) MCF-7 cells
has also been described, with increased activity of forkhead box protein O3 (FOXO3) and upregulation
of three FOXO3 target genes, Bcl-2-like protein 11 (BIM), fas cell surface death receptor (FAS) ligand
(FASL), and Gadd45a (BIM and FASL mediate intrinsic and extrinsic apoptosis respectively and
Gadd45a causes cell cycle arrest at the G2/M phase) [128]. Other signaling pathways identified in the
apoptotic response to estradiol include estradiol mediated inhibition of PI3K/AKT signaling, nuclear
factor kappa b subunit 1 (NF-κB) signaling and the c-Jun N-terminal kinase (JNK) pathway [126].
9. Potential Predictive Markers of Response to Androgen Therapy
9.1. Androgen Receptor
High AR levels appear to sensitize a number of PC preclinical models to the inhibitory effect
of SPT, raising the possibility that tumor AR expression might be useful in predicting response
to SPT. Consistent with this hypothesis, high baseline PSA levels were associated with response
in the BAT CRPC study, suggesting that SPT responders may have more active AR-signaling [9].
However, as discussed above, not all high AR CRPC models are inhibited by SPT in preclinical studies.
The ARCaP cell line expresses low levels of AR yet shows a strong androgen-dependent growth
suppression [62], while, studies in AR-expressing PC-3 cells have shown that a growth-inhibitory
effect was observed in clonal lines expressing low, moderate and high levels of AR [73], indicating that
growth inhibition was not necessarily related to the level of AR overexpression. Furthermore, studies
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in DU145, a castration resistant PCa cell line that lacks AR, have shown that ectopic overexpression of
AR in this cell line failed to yield a growth response to androgen [129].
These data indicate that AR expression by itself is not necessarily correlated with androgen-driven
growth suppression, and that a cell must possess the appropriate molecular mechanisms to engage AR
as a growth suppressor or as an oncogene [69]. As discussed above, a clear association between
response to BAT and modulation of AR-FL or AR-V7 transcript levels was not observed [11],
suggesting AR-FL or AR-V7 levels are not a biomarker of SPT response, and the predictive value of
AR signaling has yet to be fully evaluated.
9.2. DNA Damage Response Genes
As discussed above, preclinical data suggest the induction of dsDNA breaks may be a mechanism
mediating the anti-tumor effects of BAT, and an extreme response to BAT in a patient with inactivating
mutations in the DNA damage response (DDR) genes ATM and BRCA2 has been reported [121].
However, 50% of men on the BAT studies showed response and it is unlikely all of these had DDR
deficiently. Thus the extent to which DDR deficiency predicts for response to SPT-based therapy
remains unknown, but may identify a population of patients likely to show the strongest response as
well as those most likely to benefit from the combination of SPT with PARP inhibition.
9.3. Steroid Metabolism and Transport Genes
Earlier trials using physiologic dose T showed limited clinical activity compared to the
supraphysiologic levels achieved in the BAT studies, suggesting the anti-tumor efficacy of SPT may
reflect the level of intratumoral androgens achieved on therapy, an effect that may be influenced by
steroid transport and metabolizing enzymes such as SLCO1B3 and UGT2B17. Expression and/or
genetic variation in SLCO1B3 can modulate cellular T uptake in PCa cells in vitro, and genetic variants
of SLCO1B3 linked to more efficient T uptake were associated with a shorter time to progression in
men with CRPC on ADT [130,131]. In context of SPT, more efficient tumoral T uptake might associate
with an enhanced therapeutic response.
UGT2B17, responsible for the irreversible glucuronidation and ensuing elimination of T and DHT,
is highly polymorphic and deletion variants of this enzyme (primarily expressed in the liver) are
known to influence circulating steroid levels [132]. As such, patients with deletion variants might
sustain higher serum androgen levels following exogenous T dosing. UGT2B17 is also expressed in
primary and CRPC tumors, where its in situ tumor activity could also influence the maintenance of
tumor androgen levels [133,134]. Thus, genetic variation in genes such as SLCO1B3 or UGT2B17 may
serve as predictors of response to SPT.
10. Future Directions
Although a significant body of preclinical evidence, and emerging clinical data, support the
concept of high dose androgen therapy for the treatment of CRPC, a number of important questions
remain unanswered. What is the optimal dosing schedule of T therapy? Given the diversity of
mechanisms observed in preclinical studies, what are the specific mechanisms mediating clinical
anti-tumor efficacy in a particular individual? Can rational drug combinations be designed to improve
efficacy or sensitize tumors that are not inhibited by high dose androgen alone? Can biomarkers be
identified to predict response or resistance to SPT? What, if any, is the impact of stromal AR signaling
on the response to high dose androgen therapy?
The relative success of the modern studies employing the BAT approach are encouraging,
but the extent to which the clinical benefit observed in these studies reflects the bipolar dosing
strategy or the documented achievement of truly supra-physiological androgen levels remains unclear.
Preclinical studies have consistently found that SPT delivered on a continuous basis represses the
growth of PCa cells, and no studies (preclinical or clinical) have directly compared continuously
administered SPT with BAT. Whether rapid cycling of SPT (vs. continuous SPT) is necessary to achieve
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the clinical benefit or delays resistance by preventing adaptive AR-downregulation remains to be
determined. Ultimately, the predominant mechanism of SPT action may dictate the ideal dosing
strategy, with continuous treatment likely providing improved efficacy if the main mechanism of SPT
action relates to changing from a “low-T” oncogenic AR transcriptome to that of a more differentiating
SPT transcriptome [97], and BAT demonstrating more activity if repeated cycles of DNA damage is
a critical mechanism of action. However, continuous SPT can repress the expression of genes that
repair DNA damage, and thus the continuous repression of these repair programs may also exceed the
responses seen with BAT.
Understanding the mechanisms driving the anti-tumor efficacy of high dose androgen is
particularly relevant for designing rational drug combinations. For example, the observation that
androgens can induce DSB in conjunction with a recent report of an extreme response to BAT in a patient
with inactivating ATM and BRCA2 mutations, provides support for the concept that DNA damage can
sensitize to SPT [121]. These data provide a clear rationale for combining SPT with DNA damaging
agents such as PARP inhibitors (PARPi) and such a trial is currently being designed. However, rational
combinations based on other proposed mechanisms can also be conceived, including combinations
with cell cycle inhibitors to promote the impact of high dose androgen in mediating cell cycle arrest,
combinations with MYC inhibitors to promote the MYC-repressing effects of high dose androgens,
or combinations with proteasome inhibitors to prevent AR degradation and promote the proposed
stabilization of AR on DNA and inhibition of DNA licensing induced by high dose androgens.
A further consideration which merits discussion is the potential for aromatase-mediated
conversion of exogenous T to E2. PCa cells can variably express one or both of ER-alpha (which can
promote PCa proliferation) and ER-beta (which can inhibit PCa proliferation); thus the net effect of a
possible increase in estrogen signaling may be adverse or beneficial depending on the relative level of
each [66]. Whether this is a clinically relevant concern is unclear, as the extent to which T undergoes
intra-tumoral conversion to E2 in men treated with SPT is unknown. However, studies testing the
combination of T with an aromatase inhibitor (either upfront or at evidence of disease progression)
would be informative.
The potential ability of T therapy to re-sensitize CRPC tumors to AR-axis inhibition is intriguing,
and if borne out, may represent an important clinical approach for delaying disease progression.
Illustrating the potential ability of androgen-repletion to ‘ug’ mechanisms of androgen sensitivity,
culture of the androgen-repressed LNCaP 104-R1 cells in androgen rich media gave rise to a subline
that was again androgen-sensitive for growth [80]. (Importantly, the related androgen-repressed
LNCaP 104-R2 line passaged under similar androgen rich conditions gave rise to a subline that
was androgen-insensitive for growth or repression, demonstrating that androgen induced effects on
androgen sensitivity are not uniform.) In clinical studies a high response to AR-signaling inhibition was
seen in men after BAT therapy [9,11] although whether this reflects a change to a more differentiated
phenotype or specific changes in the AR/co-regulator signaling apparatus resulting in re-establishment
of androgen-sensitivity remains to be determined.
Finally, preclinical studies of androgen-mediated PCa repression have largely been carried out
in vitro or in subcutaneous xenograft models, systems which do not take into account the role of
in situ stromal AR signaling on PCa behavior [135]. Notably, multiple studies have found that
lower AR expression in PCa stroma is associated with disease progression and/or worse outcome,
implying that stromal AR is protective [136]. Mechanistically, in the absence of stromal AR signaling,
the fibroblast-derived extra-cellular matrix (ECM) was shown to have a decreased capacity to promote
attachment of both myofibroblasts and cancer cells, and was less likely to impede cancer cell
invasion [137]. In a separate study, AR-depleted cancer associated fibroblasts (CAFs) promoted
increased stem cell marker expression in human PCa cells, apparently via increased levels of Interferon
gamma (IFN-γ) and macrophage colony-stimulating factor (M-CSF) [138]. Thus, to the extent AR
signaling in PCa stroma maintains an ECM microenvironment inhibitory to cancer cell invasion,
or restrains induction of stem cell characteristics, enhanced AR-mediated stromal signaling may also
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contribute to the anti-tumor activity of high dose androgen therapy observed in clinical studies. To date
these hypotheses remain unexplored.
11. Conclusions
Meaningful clinical responses have now been observed in men with PCa treated with high
dose T, but studies designed to determine the molecular mechanism(s) driving these responses and
identify predictive biomarkers are needed in order to optimize this approach and identify rational
treatment combinations.
The clinical utility of potential treatment combinations will clearly depend on the relative
importance of the various proposed mechanism, and the extent to which the diversity of mechanisms
observed in the laboratory is recapitulated in human tumor specimens. Clinical studies with built-in
collection of biospecimens will be critical to assessing the molecular changes associated with response
or resistance to SPT, and for identifying potential predictors of response. There may be subsets of
men whose tumors will be variably responsive to SPT or particular combinations based on the
status of steroid transport and metabolizing genes, DNA damage repair genes, AR expression,
MYC dependence, and/or RB loss or alterations in other cell cycle regulators. Ultimately, high dose T
therapy is likely to represent yet another avenue for applying the principles of precision medicine for
optimizing the care of men with CRPC.
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Appendix A
Appendix A.1. Preclinical Observations on Androgen-Mediated Growth Repression of Prostate Cancer
Preclinical studies demonstrating the repressive effect of androgen on prostate cancer growth
are summarized in the primary text of the manuscript. For the interested reader, and to more fully
illustrate the similarities and heterogeneity of response observed, a more detailed review of findings in
each pre-clinical model is provided in this Appendix A and summarized in Appendix A Table A1.
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Table A1. Preclinical Responses to Androgen-Mediated Growth Repression.
Cell Line Source Derivation In Vitro Growth Characteristics In Vivo GrowthCharacteristics Refs.
LNCaP
Lymph node metastasis in a
50-year-old Caucasian male
with CRPC
Biphasic response in CSS (peak stimulation
at 0.1 nM DHT, progressive growth
suppression at 1 nM to 100 nM).
Androgen repressed in 5% FBS
[78,139,140]
104-S LNCaP Parental Line
Similar to original report
Biphasic response in CSS (peak stimulation
at 0.1 nM R1881, growth suppression at
higher doses)
In vivo growth stimulated
by androgens [7,58]
104-R1 LNCaP 104-S Passage in CSS × 10 mo Proliferated more rapidly than 104-S cells in
CSS
Severely growth repressed by 0.1 nM or
higher R1881 doses
In vivo growth inhibited
by androgens [7,57,58]
104-R2 LNCaP 104-S Passage in CSS × 18 mo
R1Ad LNCaP 104-R1 Re-growth in castrate miceafter T treatment in vivo
Lost androgen-repressed phenotype
Androgen sensitive for growth [141]
R2Ad LNCaP 104-R2 Re-growth in castrate miceafter T treatment in vivo
Lost androgen-repressed phenotype
Androgen insensitive for growth-not
affected by R1881 or bicalutamide
[80]
MOP LNCaP Passage (of LNCaP passage25 cells) in CSS × 10–12 mo Androgen insensitive for growth
Dose-dependent growth suppression in
response to R1881 at 0.1 to 10 nM
In vivo growth inhibited
by androgens [75]
JAC LNCaP Passage (of LNCaP passage55 cells) in CSS × 10–12 mo [76]
ME MOP Regrowth in castrate miceafter T treatment in vivo
Still showed androgen repressed growth
in vitro [76]
LNCaP-abl LNCaP Long term passage in CSS
Biphasic response but with higher sensitivity
than parental LNCaP (max proliferation at
0.001 nM R1881 vs. 0.01 nM)
[142]
CWR22
Primary PCa tumors initially
injected subcutaneously into
nude mice supplemented with
T, then serially transplanted as
cell suspension
Biphasic response to androgen, with optimal
proliferation at 25 to 35 nM testosterone and
growth repression at concentrations higher
than 35 nM
[61,143,144]
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Table A1. Cont.
Cell Line Source Derivation In Vitro Growth Characteristics In Vivo GrowthCharacteristics Refs.
CWR22R CWR22
Derived from a CWR22
tumor showing castration
resistant re-growth in vivo
Not consistently stimulated by androgen
Growth repressive effect left-shifted vs.
parental CWR22 line, with repression
induced at T levels of approximately 25 nM
[145]
22RV1 CWR22R Androgen-sensitive for growth without abiphasic response [63]
ARCaP (MDA
PCa 1)
Isolated from the ascites fluid of
an 83-year-old Caucasian man
with metastatic CRPC
Highly androgen-repressed growth (starting
as low as 100 pM DHT) despite relatively
low AR expression
Grew 3 times faster in
castrated hosts than in intact
male hosts; growth in
castrated hosts was
suppressed by exogenous T
[62]
VCaP From a vertebral metastatic lesionof patient with CRPC
40% repression at 10 nM R1881. Detachment
and disintegration of cells passaged in low
androgen conditions (10% FBS) when treated
with 1 nM T in vitro
Poor growth in intact
(noncastrate) SCID mice [56] [56,67,146]
E006AA
From primary tumor of a
50-year-old African-American
man with clinically localized PCa
Biphasic response, with proliferative
response as low as 1 fM DHT and maximal
proliferative at 0.1 pM DHT
[147]
MDA PCa 2b From a bone metastasis of apatient with CRPC
Biphasic response, peak proliferation at
10 nM DHT with growth inhibitory effects at
higher concentrations
Stopped growing or
decreased in size after
castration (response to high
dose androgen not evaluated
in vivo)
[59,60]
MDA PCa 2b-hr MDA PCa 2b culture of MDA PCa 2b inCSS for 35 weeks
Biphasic response to T concentrations
ranging from 0.1 ng/ml to 1000 ng/ml,
with maximal proliferation 1 ng/mL T
[60]
RC-77T
From primary tumor of a
63-year-old African American
man with clinically localized PCa
Biphasic response, maximal growth at
0.1 nM R1881 and growth inhibition at
higher doses
[148]
PC3-AR From lumbar vertebral metastasisof a 62-year-old white man
PC3 with exogenous
expression of AR
Androgen mediated growth repression at
DHT 0.1 nM
In vivo growth inhibited by
androgen levels presesnt in
intact male mice
[129,149–151]
CSS: charcoal stripped serum; DHT: dihydrotestosterone; FBS: fetal bovine serum; AR: androgen receptor; SCID: severe combined immunodeficiency; PCa: prostate cancer;
MDA: MD Anderson.
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Appendix A.1.1. LNCaPs
Derived from a supraclavicular lymph node metastasis in a 50-year-old Caucasian male [139],
LNCaP is the most widely used cell line in prostate cancer research. A number of sublines have
been derived under different culture conditions and with varying degrees of sensitivity to androgen
induced growth and repression. Horoszewicz et al. originally reported the stimulatory effect of DHT on
LNCaPs in androgen-depleted conditions 5% charcoal stripped serum (CSS) and the dose-dependent
suppression in response to DHT in cells cultured in relatively androgen-rich conditions (5% FBS) [140].
De Launoit et al. also demonstrated a progressive decrease in the stimulatory effect of DHT (in 2% CSS)
at doses higher than 0.1 nM, returning to basal levels with doses between 1 nM and 100 nM [78].
I. LNCaP 104-S, 104-R1, 104-R2, R1Ad, R2Ad
Similarly, androgen sensitive LNCaP 104-S cells showed maximal proliferation at 0.1 nM R1881
(with progressive growth suppression with higher doses), while 104-R1 and 104-R2 cells (derived
after passages in androgen-depleted medium for 10 months and 18 months, respectively) proliferated
more rapidly than 104-S cells in androgen-free conditions, and were severely inhibited by 0.1 nM
or higher R1881 doses [57,58], illustrating the left-shift in androgen-repressed sensitivity frequently
observed in the transition from androgen-sensitive to androgen-insensitive cell growth. Consistent
with the in vitro data, proliferation of LNCaP 104-S tumors in vivo was stimulated by androgens but
testosterone propionate (TP) pellets implanted in castrated nude mice bearing LNCaP 104-R2 resulted
in tumor growth inhibition and a significantly reduced tumor size [7].
Interestingly, when re-passaged in androgen-rich conditions (castrated mice bearing T pellets),
104-R1 cells (now called R1Ad) lost the androgen-repressed phenotype and showed androgen-induced
growth in vivo, illustrating the potential ability of androgen-repletion to ‘re-engage’ mechanisms of
androgen sensitivity. In contrast, however, 104-R2 cells passaged in androgen-rich conditions gave
rise to the androgen-insensitive R2Ad subline, the growth of which was not affected by R1881 or the
anti-androgen bicalutamide [80], demonstrating that androgen-induced effects on androgen sensitivity
are far from uniform.
II. MOP, JAC, ME
LNCaP variant MOP and JAC cells (derived, respectively, by continuous passaging of
androgen-sensitive LNCaPs at passage 28 and 55 in 2.5–5% CSS for 10–12 months), were androgen-
insensitive for growth, and showed dose-dependent growth suppression in response to R1881 at 0.1 to
10 nM [75,76] Similarly, testosterone treatment delayed the take of palpable tumors following injection
of LNCaP variant MOP cells in female nu/nu mice in vivo. Notably, tumors eventually escaped
treatment, but ME cell lines, established from these non-testosterone repressed tumors still showed
androgen repressed growth in vitro [76].
III. LNCaP-abl
Similar to androgen-sensitive LNCaP cells, LNCaP-abl, another subline derived from long-term
passage in CSS, demonstrated a biphasic response to androgen, but with a higher sensitivity than
the parental LNCaP [142], again illustrating the left-shift in androgen-repressed sensitivity observed
in the transition from androgen-sensitive to androgen-insensitive cell growth. While the maximum
proliferative rate of the parental LNCaP was achieved at 0.01 nM R1881, the R1881 dose that achieved
maximal proliferation of the abl subline was left-shifted one order of magnitude to be at 0.001 nM.
Moreover, at passages higher than 75, androgen treatment only induced an inhibitory growth effect on
the LNCaP-abl subline [142].
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IV. C4-2B
The C4-2B cell line was isolated from a mouse vertebral metastasis in 1994 as a subline of a LNCaP
derivative established by Wu et al. [151]. Wu et al. co-injected LNCaP and osteosarcoma cell lines
subcutaneously in intact mice, followed by castration, resulting in growth of an androgen-independent
tumor. Cells cultured from these tumors, denoted C4 cells, were then subcutaneously injected in
castrate mice, giving rise to tumors from which the C4-2 cells were cultured. Following subcutaneous
or orthotopic injection of C4-2 cells into castrated mice, cells isolated from a vertebral bone metastasis
were cultured and denoted C4-2B [152]. Although Thalmann et al. reported that the osseous metastases
of the androgen-independent C4-2 cells (C4-2B) were enhanced in castrated hosts, suggesting androgen
suppression of androgen-independent dissemination [152], Pfitzenmaier et al. later reported that the
growth of C4-2 metastases was inhibited by androgen suppression i.e., castration [153].
Appendix A.1.2. CWR22 and CWR22R
CWR22 is a serially transplantable xenograft established along with other CWR lines from primary
tumors excised through transurethral resection of the prostate or radical prostatectomies, and [143,144].
However, it has been since transplanted through injection of the cell suspension into testosterone
supplemented nude mice [144]. After castration, the xenograft markedly regresses, but is often
followed by tumor relapse 3 to 10 months after castration [61,145], from which the CWR22R line
was derived.
Nagabhushan et al. reported the differential sensitivity of CWR22 and CWR22R cells to androgen
stimulation in soft agar [61], again illustrating the left-shift in androgen-repressed sensitivity observed
in the transition from androgen-sensitive to androgen-insensitive cell growth. CWR22 cells showed
a biphasic response to androgen, with optimal proliferation at 25 to 35 nM testosterone and growth
repression at concentrations higher than 35 nM [61]. Growth of CWR22 in FBS was parallel to CSS
curves, with more overall cell proliferation in FBS. In both media, T concentrations higher than 35 nM
inhibited proliferation [61]. In contrast, CWR22R cells were not consistently stimulated by androgen
and the growth repressive effect was left-shifted compared to the parental CWR22 line, with repression
induced at T levels of approximately 25 nM [61]. In contradistinction to CWR22 cells, 22Rv1, another AI
line derived from CWR22R, is androgen sensitive for growth without a biphasic response [63].
Appendix A.1.3. ARCaP
Isolated from the ascites fluid of an 83-year-old Caucasian man with metastatic PCa, the highly
metastatic ARCaP cell line, also known as MDA PCa 1, was first introduced and characterized by Zhau
et al. in 1996 [62] and is notable for its highly androgen-repressed phenotype despite relatively low AR
expression. ARCaP cells have been reported to demonstrate growth repression to DHT in vitro in a
concentration-dependent manner (starting as low as 100 pM) [62]. Interestingly, overexpression of AR
in these cells restored a biphasic response to androgen, with stimulation of proliferation in response to
R1881 at 0.1 nM to 10 nM but suppression of proliferation at higher R1881 concentrations of 100 nM to
1 uM R1881 [72]. ARCaP tumors, when maintained as subcutaneous xenografts, grew 3 times faster in
castrated hosts than in intact male hosts, suggesting the sensitivity of these cells to suppression by
physiological levels of androgen. Consistent with the in vitro assays, tumor growth in castrated hosts
was suppressed by subcutaneous administration of either testosterone propionate [62].
Appendix A.1.4. VCaP
These cells were isolated in 2001 from a vertebral metastatic lesion of a patient with CRPC.
Initial studies characterizing this line demonstrated it was androgen sensitive for growth in vitro
and in vivo but did not report a biphasic response [146]. Subsequent studies by several groups have
demonstrated the ability of high dose androgen to repress growth in this model. Denmeade showed
40% repression of growth after 5 days of exposure to 10 nM R1881 [67]. Thelen et al. demonstrated
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detachment and disintegration of VCaP cells passaged in low androgen conditions (10% FBS) when
treated with 1 nM T in vitro, and poor growth when injected subcutaneously in intact (noncastrate)
severe combined immunodeficiency (SCID) mice [56].
Appendix A.1.5. E006AA
This cell line was established by Koochekpour et al. as spontaneously immortalized cells from a
50-year-old African-American patient who underwent radical retro-pubic prostatectomy for treatment
of a clinically localized prostate cancer [147]. In vitro studies have shown a biphasic response of
E006AA to androgen, with the cells being much more sensitive to DHT stimulation (in 1% CSS) than
were LNCaP cells. The proliferative response of E006AA started at concentrations as low as 1 fM DHT,
with a maximal proliferative effect at 0.1 pM, while higher DHT concentrations had an inhibitory effect
on cell number compared with untreated cells [147].
Koochekpour et al. reported E006AA cells were non-tumorigenic in vivo when xenografted in
athymic nude mice [147]. D’Antonio et al. subsequently showed that these cells tumorigenic in the
NOD-SCID-IL2Rgamma (NSG)triple deficient mice, attributing the failure of growth in the original
studies to the fact that nude mice possess high levels of activated natural killer T-cells, resulting in
increased host-immunoreactivity towards a growing tumor [154]. Moreover, and despite having been
isolated from a hormonally naïve primary prostate cancer, E006AA cells showed castration-resistant
growth when xenografted in castrated vs. intact NSG mice [154]. However, the response of tumors to
exogenous androgen in vivo, either in castrated or intact mice, has not been assessed.
Appendix A.1.6. MDA PCa 2b and MDA PCa 2b-hr
MDA PCa 2a and 2b were derived from a bone metastasis of a patient with castration resistant
prostate cancer. Both lines express AR, grow in vitro and in vivo, and are androgen sensitive [59].
Both lines demonstrate peak proliferation in response to DHT at 10 nM with growth inhibitory effects
at higher concentrations [59].
The MDA PCa 2b-hr cell line was derived from the androgen-dependent MDA PCa 2b cell line
after prolonged culturing in androgen-depleted media [60]. Hara et al. reported the biphasic response
of MDA PCa 2b-hr cells to testosterone concentrations ranging from 0.1 ng/mL to 1000 ng/mL, with the
maximal proliferation rate achieved with 1 ng/mL of testosterone [60]. Navone et al. reported that
MDA PCa 2b tumors formed in athymic mice stopped growing or decreased in size after castration [59].
Conversely, Hara et al. reported that in nude mice bearing MDA PCa 2b tumors, treatment with a
100 mg DHEA pellet (which achieved a 12.4 ng/mL serum testosterone levels, comparable with the
physiological levels in uncastrated men) stimulated MDA PCa 2b growth. However, the effect of
exogenous high-dose androgen on tumor growth in castrated conditions has not been assessed in
this model.
Appendix A.1.7. RC-77N/E & RC-77T/E
These cell lines were first introduced by Theodore et al. in 2010 [155]. Tumor tissue (RC-77T)
and non-malignant tissue (RC-77N) used for generating the cell lines that were obtained from a
radical prostatectomy specimen of a 63-year-old African American patient with a clinical stage T3c
adenocarcinoma with poor differentiation (Gleason 7) [155]. Androgen sensitivity assays were carried
out in keratinocyte serum-free media (K-SFM) in the presence of 0, 0.1, and 1 nM R1881. RC-77T
cells were shown to be more sensitive to androgen stimulation, reaching a peak growth with 0.1 nM
R1881, than were RC-77N cells, which reached their peak growth with 1 nM. Higher doses (10–100 nM
R1881) seemed to inhibit cell growth [155]. Effects of exogenous androgens on growth in vivo have
not been reported.
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Appendix A.1.8. PC-3
PC-3 cells were first derived by Kaighn et al. from a lumbar vertebral metastasis in a 62-year-old
white man in 1979 [148]. Although the original PC-3 cell line lacks AR, multiple studies have used
exogenous AR expression in PC-3 cells to investigate the role of AR in the androgen-mediated growth
response of the cells. Early studies reported that ectopic expression of AR using a viral promoter in
PC-3 cells led to androgen-mediated suppression of cell growth [73,156,157]. Yuan et al. first reported
more than a 50% decrease in proliferation of PC-3 cells transfected with human full length AR when
treated with 2 ug /mL (6.8 uM) DHT for 72 h, and more than 40% inhibition of cell proliferation
with DHT doses as low as 0.1 nM after a 72 h incubation [156]. These findings were confirmed later
by Litvinov et al. using a modified expression vector for the exogenous AR expression [129,149].
Interestingly however, Altuwaijri et al. reported an otherwise slight androgen-induced cell growth
of PC-3 cells expressing AR driven by its natural human AR promoter, denoted PC-3(AR)9 cells,
when treated with 1 nmol/L DHT [150]. To confirm the AR-mediated growth inhibition in animal
models, Litvinov et al. xenografted Lenti-AR PC-3 cells and control cells into male nude intact mice.
PC-3-Lenti-AR tumors in mice were profoundly growth inhibited in comparison with PC-3 control
tumors [129].
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